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Background. The use of a single troponin measurement to exclude the diagnosis of non-ST segment myocardial infarction
(NSTEMI) in patients that present with ischemic symptom duration ≥8 hours is sometimes used in the Emergency Department.
Study Objective. To describe the characteristics of patients with initial nondiagnostic troponin values who develop a positive
troponin while in the Emergency Department and to evaluate whether NSTEMI can be excluded using symptom duration ≥8
hoursandinitialtroponin I.Methods.Retrospective chart review of patients evaluatedforNSTEMI in theEmergency Department.
Results. 4,510 patients had at least two troponin I values obtained during the two-year study period. 115 (2.5%) of these patients
had an initially nondiagnostic (<0.6ng/mL) and subsequent positive (≥0.6ng/mL) troponin I result. Twenty-ﬁve (22%) of the
115 had duration of symptoms ≥8 hours. Of these 25 patients, 18 had an intermediate ﬁrst troponin value (i.e., >0.06ng/mL, but
<0.6ng/mL).Onlytwo oftheremainingsevenpatients hadaﬁnalprimary diagnosisofNSTEMI. Conclusion.T heu seofane g at i v e
initialtroponin Itogether with a symptomonsetof ≥8hours deﬁnes a populationwith a very lowincidence ofa hospitaldiagnosis
of NSTEMI.
1.Introduction
1.1. Background and Importance. Troponin has become the
preferred cardiac biomarker with respect to the diagnosis
of acute myocardial infarction (AMI) [1–3]. This serum
protein of cardiac cell necrosis appears 4 to 12 hours
after symptom onset and remains abnormal for 4 to 10
days [4, 5]. To avoid missing early myocardial damage
in patients with normal or nondiagnostic electrocardio-
grams, physicians routinely employ the use of serial tro-
ponin measurements initially on arrival to the emergency
department (ED) and subsequently at a time frame of 6
to 12 hours after the onset of ischemic symptoms. The
precise timing of serum marker measurement, however,
must take into account the uncertainties often present with
the exact timing of onset of ischemic symptoms and the
sensitivity, precision, and institutional norms of the assay
being utilized. A strategy of measuring cardiac markers
within 6 hours of symptom onset with repeat measurements
occurring 8 to 12 hours after symptom onset is recom-
mended by the American College of Cardiology/American
Heart Association (ACC/AHA) and is thought to approach
100% sensitivity for excluding the diagnosis of AMI
[3].
The American College of Emergency Physicians (ACEP)
has published a clinical policy that supports the use of a
single negative TnI obtained 8 to 12 hours after symptom
onsetfortheexclusionofnon-ST-segment elevationmyocar-
dial infarction (NSTEMI). There are, however, relatively few
published reports substantiating the safety of this approach.
Furthermore, a review of the use of troponin T in this
setting was unable to conﬁrm the safety of this approach [6].
Additionally, there has been no published research deﬁning
thepopulationofpatientswho presentwithaninitialnormal
TnI who then develop an elevated value on subsequent
testing. As such, little is known about the demographic, his-
torical, physical exam, electrocardiographic, and laboratory
features of these patients.2 ISRN Cardiology
1.2. Goals of This Investigation. We sought to deﬁne the
frequency and clinical characteristics of ED patients with
an initial nondiagnostic, but subsequent positive TnI. In
addition, we sought to determine what percentage of the
aforementionedpatientspresentedwithasymptomduration
greater than 8 hours. These patients reﬂect a population that
the ACEP guidelines for the diagnosis of NSTEMI would
have failed to recognize.
2.Methods
2.1. Study Design and Setting. All data for this study was
obtained through a systematic review of the electronic and
paper medical record (when available) for patients evaluated
in the emergency department of a single urban county
teaching hospital with an annual census of approximately
80,000 visits. Two authors (J. S. Lynn and A. Singh)
conducted the data abstraction using a standardized data
abstraction worksheet. Approval for this study was granted
by the institutional review board at our institution, prior to
the commencement of data acquisition.
2.2. Selection of Participants. Patients were included in this
study if they presented to the emergency department (ED)
between January 2004 and December 2005 and fulﬁlled all
of the following criteria: (1) had at least two TnI laboratory
values obtained, (2) the ﬁrst TnI value was ≤0.6ng/mL,
and (3) any subsequent troponin I value in the ED was
>0.6ng/mL. There were no exclusion criteria. A laboratory
database of all TnI results obtained during the study period
was used to identify participants.
2.3.Troponin Assays. FromJanuary 2004throughSeptember
2005 the Stratus stat-ﬂuorometric analyzer (Dade-Behring)
was used to measure troponin values. The analytical lower
threshold for detection for this method was 0.03ng/mL,
the laboratory reference range extended to 0.06ng/mL, and
the threshold for suspecting acute myocardial infarction
was ≥0.6ng/mL [7]. After September 2005, TnI values
were determined with the Access 2 (Beckman-Coulter).
The analytical lower detection threshold and interpretive
ranges remained the same. TnI measurements that were
<0.6ng/mL were labeled as “negative” for AMI, whereas
those≥0.6ng/mLwereconsidered“positive”forAMI.Values
betweenthelowerthresholdfordetection(i.e.,≥0.06ng/mL)
but less than the diagnostic cutoﬀ for AMI (i.e., <0.6ng/mL)
were considered “intermediate”.
2.4. Data Collection and Processing. Data was collected
directly onto a standardized secure computerized database.
Source documents included all parts of the ED electronic
medical record, including triage notes, nursing notes, any
physician notes, and laboratory data. In addition, the paper
record was reviewed for each subject including the ED
physician’s history and physical (H&P), admitting resident’s
H&P, consulting specialist’s H&P, and both the written and
dictated discharge summary (when available).
Discrepancies among the medical records for a given
subjectwerereconciledaccordingtothefollowingpredeﬁned
rules. If one or more source listed a given condition in the
patient’s past medical history, it was recorded as present;
otherwise, it was recorded as absent. When determining
the duration of symptoms, the most speciﬁc time of onset
recorded by any provider was used (i.e., 9AM instead of
“this morning”). If two sources had equal speciﬁcity, then
the later time was recorded. When nonspeciﬁc times of the
day were all that was available, preassigned times were used
as follows—“last night” = 8PM, “this morning” = 8AM,or
“this afternoon” = 2PM.
The duration of symptoms was deﬁned as the duration
of time between the onset of symptoms for which the patient
presented to the EDand arrival in the ED.Forexample, ifthe
patient had worsening chest pain for 2 days, and eventually
came to the ED, the duration of symptoms was deﬁned as
2 days. However, if a patient had shortness of breath for
one week and developed chest pain 3h prior to arrival, the
duration of symptoms was recorded as 3h.
ECGs were recorded as either diagnostic or non-
diagnostic of ischemia. ECGs were considered diagnostic of
ischemia if they were recorded by the treating physicians
as having any one of the following, not known to be old:
>0.2mV ST depression in 2 or more contiguous leads,
>0.1mV ST elevation in 2 or more contiguousleads, or a left
bundle branch block.
2.5. Data Analysis. Data was analyzed using descriptive
statistical analysis.
3.Results
Five thousand ﬁve hundred and ninety-six patients present-
ing to the ED during the study period that had at least one
TnI obtained. One thousand and eighty-six patients did not
have a second TnI obtained and were therefore excluded. Of
the remaining 4,510 patients, 4,208 (93.3%) did not have
any TnI levels greater than 0.6ng/mL. This left a total of 302
(6.7%) patients that had at least one TnI value ≥0.6ng/mL.
Of these 302 patients, 187 (61.9%) had an initial troponin
I value that was ≥0.6ng/mL and were therefore excluded
from analysis. The remaining 115 patients were the group
of patients who had at least two TnI values obtained, with
the ﬁrst value <0.6ng/mL and at least one subsequent value
≥0.6ng/mL. These patients comprised the study population
(Figure 1).
Ninety (78.2%) patients had their positive troponin
drawn within 8 hours of the ﬁrst sample. Of the remaining
25 patients that required >8 hours, 11 were not positive until
three or more TnI values were obtained.
Thecharacteristics ofthestudypopulationincludingage,
gender, race, and signiﬁcant past medical history are listed
in Table 1. Traditional cardiac risk factors—hypertension,
diabetes, active smoking, hyperlipidemia, or family history
of early MI were present in 86.1% of patients with 26.1%
having 3 or more concomitant risk factors. If cocaine use,
prior stroke, or prior MI were considered in addition to
the traditional cardiac risk factors, the percentage of study
patientswithatleastonecardiacriskfactor increasedto93%.ISRN Cardiology 3
5,596 patients had TnI
o b t a i n e di nt h eE D
1,086 excluded-
discharged after single
negative TnI
4,510 patients had two TnI
obtained whilein the ED
4,208 excluded-both sets
of TnI were negative
302 patients with at least
one TnI value ≥ 0.6ng/mL
187 excluded-initial
TnI ≥ 0.6ng/mL
115 patients with at least two TnI
who had initial TnI value < 0.6ng/mLand
subsequent value ≥ 0.6ng/mL
Figure 1
Table 2 summarizes the characteristics of the study
population upon arrival to the ED. In our institution,
patients are activated as a “medical code” if they are thought
to require immediate physician and nursing interventions
for an unstable medical condition. Forty-seven (40.9%) of
the study patients were activated as a medical code. Nine
(7.8%) patients were brought in to the hospital as trauma
activations. Symptoms were considered “ongoing” if the
patient was symptomatic at the time of arrival to the ED.
All but 6 patients had ongoing symptoms upon arrival to
the ED. These 6 patients all presented after a fall or syncope.
The majority of patients (53.0%) had less than 1 hour
of symptoms upon arrival to the ED. Ninety-one (79.1%)
patients had less than 8 hours of symptoms. That leaves 25
(21.7%) patients who presented with an initial negative but
subsequent positive TnI (≥0.6ng/mL) and had ≥8 hours of
symptoms upon arrival to the ED.
Selected details regarding the hospital course of these 25
patients are presented in Tables 3 and 4. All 25 had ongoing
symptoms upon arrival to the ED. Sixteen of the 25 patients
had a ﬁnal primary diagnosis other than acute coronary
syndrome. Only one of the patients listed on Table 4 died
during the hospital admission—a 73-year-old woman who
suﬀered a massive pulmonary embolism.
Although 0.6ng/mL is considered the “cutoﬀ”f o rt h e
diagnosis of acute MI, the 99th percentile of the upper
limit of the TnI reference range for a healthy population is
0.06ng/mL—an order of magnitude lower than the cutoﬀ
for AMI. Forty-eight (41.7%)patients of the 115 in the study
had an initial troponin that was <0.06ng/mL. Of those 48
patients with a true negative ﬁrst troponin, only 7 patients
had ≥8 hours of symptoms at the time of presentation.
Table 1: Characteristics of patients in the study group.
Age, y (%) N = 115
20–29 4 (3.5)
30–39 5 (4.3)
40–49 17 (14.8)
50–59 22 (19.1)
60–69 25 (21.7)
70–79 20 (17.4)
80–89 17 (14.8)
90–99 5 (4.3)
Gender (%)
Male 62 (53.9)
Female 53 (46.1)
Race (%)
African American 55 (47.8)
Hispanic 26 (22.6)
Caucasian 18 (15.7)
Asian 9 (7.8)
Other 7 (6.1)
Past Medical History (%)
Hypertension 81 (70.4)
Diabetes 41 (35.7)
Prior myocardial infarction 41 (35.7)
Hyperlipidemia 33 (28.7)
Congestive heart failure 30 (26.1)
Prior stroke 16 (13.9)
Prior cardiac catheterization 12 (10.4)
Chronic kidney disease 9 (7.8)
Prior CABG 6 (5.2)
Family history of early myocardial infarction 6 (5.2)
Substance abuse (%)
Tobacco 38 (33.0)
Cocaine 19 (16.5)
Alcohol 14 (12.2)
Injection drug use 1 (0.9)
CABG: coronary artery bypass graft.
Of all 4,510 patients that had more than one TnI
value obtained, only 7 (0.16%) had ≥8h of symptoms, an
initial troponin <0.06ng/mL and any subsequent troponin
≥0.6ng/mL. Two ofthese 7 patientshad anultimate primary
ﬁnal diagnosis of acute coronary syndrome.
4.Discussion
In 2006, the ACEP Clinical Policies Subcommittee published
guidelines for the evaluation and management of patients
with potential NSTEMI [3]. As a level B recommendation,
these guidelines support the use of “a single negative CK-
MB mass, Troponin I, or Troponin T measured 8 to 12 hours
after symptom onset” to exclude the diagnosis of NSTEMI
as deﬁned by the World Health Organization [8]. These
are the ﬁrst emergency medicine guidelines to formally link
the duration from symptom onset to the interpretation and4 ISRN Cardiology
Table 2: Presenting characteristics of the study population.
Arrival (%) N = 115
Medical code 47 (40.9)
Trauma activation 9 (7.8)
Presenting symptom (%)
Chest pain 50 (43.5)
Shortness of breath 35 (30.4)
Altered mental status 10 (8.7)
Cardiac/respiratory arrest 8 (7.0)
Syncope 4 (3.5)
Other 12 (10.4)
Duration of symptoms, h (%)
≤1hr 61 (53.0)
>1hr–≤4hr 22 (19.1)
>4hr–≤8hr 7(6.1)
>8hr–24hr 10 (8.7)
>24hr 15 (13.0)
ECG diagnostic of ischemia (%)
Yes 38 (33.0)
No 77 (67.0)
Ongoing symptoms (%)
Yes 109 (94.8)
No 6 (5.2)
ACLS (%)
Cardioversion 8 (7.0)
Chest compression 8 (7.0)
Code drugs 9 (7.8)
ACLS: advanced cardiac life support.
timing of serum markers. The subcommittee further sug-
gested that the reference range for serum markers be lowered
to the 99th percentile for the normal healthy population. For
Troponin I and T, this change would represent a near10-
fold decrease in the threshold for considering acute coronary
syndrome. The eﬀect of this recommendation has been to
increase serum marker sensitivity while raising the dilemma
of how to clinically interpret results that fall within the
abnormal range but below the traditional diagnostic cutoﬀ.
Although we believe these recommendations accurately
reﬂect recent clinical studies as well as the performance
characteristics of newer serum markers, most ED physicians
continue to employ a traditional serial biochemical marker
approach.
Although the new ACEP guidelines endorse a single
negative troponin I or T for the exclusion of NSTEMI when
measured 8 to 12 hours after symptom onset, there are only
a few trials that have directly addressed this issue. In 1997,
Hamm et al. evaluated 773 consecutive patients who pre-
sented with chest pain of <12h duration and an absence of
acute ST-elevation myocardial infarction (STEMI). Among
all patients with a negative troponin I, obtained at least 6
hours after the onset of symptoms, the event (death or MI
at 30 days) rate was 0.3% [9]. In 2001, Limkakeng et al.
attempted to prospectively use a combination of a single
Table 3: Outcomes of the study population.
Workup/treatment (%) N = 115
Cardiac Catheterization 21 (18.3)
Stress test 17 (14.8)
Thrombolysis 12 (10.4)
Primary diagnosis (%)
NSTEMI 39 (33.9)
STEMI 16 (13.9)
CHF exacerbation 9 (7.8)
Arrest 8 (7.0)
Tachydysrhythmia 5 (4.3)
Pulmonary embolism 5 (4.3)
Pneumonia 3 (2.6)
Pulmonary edema 3 (2.6)
Intracranial hemorrhage 3 (2.6)
Sepsis 3 (2.6)
Gastrointestinal bleed 3 (2.6)
Syncope 3 (2.6)
Hypertensive emergency 2 (1.7)
Stroke 2 (1.7)
Other 9 (7.8)
Death (%)
Yes 14 (12.2)
STEMI: ST segment elevation myocardial infarction, NSTEMI: non-ST
segment elevation myocardial infarction, CHF: congestive heart failure.
TnI at presentation and a Goldman risk ≤4% to identify
a subset of patients that would be appropriate for early
discharge from the emergency department [10]. Of the 2,322
patients enrolled, 998 had both an initial negative TnI and
a Goldman risk ≤4%. A total of 49 (4.9%) patients met the
composite endpoint ofdeath, AMI, orrevascularization. The
authors conclude from this study that a single cardiac TnI
was insuﬃcienttoexcludethediagnosis ofacuteMI among a
selected group of low risk patients. Also, in 2001, two articles
were published that attempted to validate accelerated clinical
pathways to excludethe diagnosis of AMI in the ED [11, 12].
In the paper by Ng et al. one arm of the accelerated pathway
was for patients with >6 hours of symptoms thought not to
be cardiac in origin. For these patients, the algorithm called
for a single TnI and an ECG. If the ECG was nondiagnostic
and the ﬁrst TnI was negative, then the patient could be
discharged home without further testing. The 30-day event
rate for all patients discharged home during the study was
0.2% for MI and 0.8% readmission for unstable angina.
The ﬁrst study to evaluate a single troponin in relation
to symptom duration was a small prospective study of 267
patients presenting to an ED with suspected myocardial
ischemia [13]. A single troponin T (TnT) was obtained at
presentation in all patients. Sixty patients were ultimately
diagnosed with AMI, based on traditional WHO criteria.
52 of these 60 AMI patients had initial positive TnT upon
presentation to the ED, revealing an overall sensitivity of
86.7% for single initial TnT. Among the 8 patients with
initially negative TnT, the duration of symptoms was alwaysISRN Cardiology 5
Table 4:Selected details of25 patients with an initial troponin value <0.6ng/mL,any subsequent troponin value ≥0.6ng/mL,and ≥8h o u r s
of symptoms.
Age gender Chief
complaint
Duration of
symptoms
Initial troponin
ng/mL
Peak troponin
ng/mL
ECG
diagnostic Diagnosisprimary, secondary
61 F SOB 2 weeks <0.06 0.74 No Asthma exacerbation
69 M SOB 3 days <0.06 0.9 No Pleural eﬀusion
75 F Chest Pain 1 day <0.06 6.49 No ACS-NSTEMI, pneumonia
49 M Rib Pain 2 weeks <0.06 1.92 No Pneumonia,cocaine abuse, and atrial
Fibrillation
22 M Abdominal
Pain 1 week 0.06 0.79 No Hypertensive emergency, renal failure,
and cocaine abuse
82 F SOB 3 days 0.06 2.38 Yes (LBBB) ACS-NSTEMI, CHF exacerbation
81 M “feeling
lousy” 10 hours 0.06 8.24 Yes (STD) Bacteremia, pneumonia, and
ACS-NSTEMI
73 F SOB 1 day 0.08 0.87 No CHF exacerbation and ESRD
70 F Abdominal
Pain 3 days 0.14 1.64 No Acute cholecystitis
60 M SOB 3 days 0.17 1.34 No CHF exacerbation and Pneumonia
38 M Chest Pain 2 days 0.17 2.32 No ACS-NSTEMI
38 F SOB 1 day 0.19 1.47 No CHF exacerbation and cocaine abuse
74 M Chest Pain 10 hours 0.22 1.24 Yes (STE) ACS-NSTEMI
64 F Chest Pain 12 hours 0.22 16.39 Yes (LBBB) ACS-NSTEMI
48 M Chest Pain 8.5 hours 0.24 3.99 No ACS-NSTEMI
60 M Chest Pain 4 days 0.25 3.30 No Gastrointestinal bleed
54 M SOB 1 day 0.31 0.89 No Pulmonary embolism and cocaine abuse
70 F SOB 1 week 0.31 0.7 Yes (LBBB) CHF exacerbation
73 F SOB 18 hours 0.35 1.13 No Pulmonary embolism
50 M SOB 2 weeks 0.43 0.76 No CHF exacerbation, cocaine abuse,
emphysema
75 F Chest Pain 1 day 0.45 0.91 No ACS-NSTEMI
67 F Chest Pain 4 days 0.48 1.12 No ACS-NSTEMI
64 M Chest Pain 2 days 0.48 3.56 No ACS-NSTEMI
49 F Found Down 22 hours 0.56 0.94 No Mechanical fall, closed head injury
83 F SOB 2 days 0.58 0.66 No Pneumonia
ACS: acute coronary syndrome, NSTEMI: non-ST segment elevation myocardial infarction, CHF: congestive heart failure.
less than 3.5h. Therefore, in this small study, the sensitivity
ofaninitialTnT todiagnosemyocardial infarction was100%
in the subset of patients with greater than 3.5 hours of
symptoms.
Although providers may be wary to discharge patients
home after a single troponin I, there has been at least one
retrospective chart review that looked at the results of 588
patients who were discharged home from the ED after a
single normal cTnI was obtained 6–9 hours after symptom
onset [14]. In this population, an adverse cardiac event (car-
diac death or MI at 30 days) occurred in 2 patients (0.34%),
bothreturnvisitsforanNSTEMI.Theauthorspointoutthat
in both of these patients, the evaluation deviated from their
group’s standard practice. The ﬁrst patient was discharged
from the ED even though the troponin sample was drawn 30
minutes after the onset of symptoms, and the second patient
was discharged home despite new ST segment depressions
on the ECGin the setting ofpresumed stable angina. Neither
patient died within 30 days.
The appropriate diagnostic cutoﬀ to use for a single
or serial marker approach, has been the subject of intense
debate. The original WHO guidelines for the diagnosis of
acute myocardial infarction use a cutoﬀ for cardiac enzymes
deﬁned as “twice the upper limit of normal” [8]. Cardiac
enzyme bioassays have matured substantially since this time.
TheEuropeanSocietyofCardiology(ESC)andtheAmerican
College of Cardiology (ACC) convened a conference in
2007 to readdress the issue of a standardized deﬁnition
for the diagnosis of AMI [15]. This committee deﬁned an
increased cardiac troponin as “a measurement exceeding
the 99th percentile of a reference control group”, meaning
that 1% of the normal population will routinely fall within
the abnormal range. They further deﬁne an acceptable
level of imprecision, or coeﬃcient of variance (CV), at6 ISRN Cardiology
Table 5: Elevations of troponin in the absence of acute myocardial
ischemia.
Cardiac trauma—for example, contusion and post-surgical
trauma
Congestive heart failure
Pulmonary embolism
Chronic kidney disease
Severe sepsis
Large burns with or without rhabdomyolysis
Acute stroke or subarachnoid hemorrhage
Cardiac inﬁltrative disease (e.g., amyloidosis,hemochromatosis,
and sarcoidosis)
Cardiacinﬂammatorydisease(e.g.,myocarditisandpericarditis)
Aortic dissection of valve disease
Hypertrophic cardiomyopathy
Cardiac dysrhythmia
the 99th percentile as ≤1 0 % .F i n a l l y ,t h en e wE S C / A C C
guidelines provide criteria for acute, evolving, or recent MI
that require a “typical rise and gradual fall” with either
ischemic symptoms, ECG changes, or a coronary artery
intervention.Theydonot,however,provideacutoﬀvaluefor
the diagnosis of MI other than the 99th percentile deﬁnition
previously described. Nevertheless, most studies of acute
MI continue to use a cutoﬀ value that is deﬁned by the
receiveroperating curve (ROC)that optimizes the sensitivity
and speciﬁcity for the exclusion of AMI, often based upon
older CK- MB standards. In some instances, the new
reference value recommended by the ESC/ACC is an order of
magnitude smaller than the previously recognized deﬁnition
for determining myocardial ischemia. It is estimated that
routine application of the new reference cutoﬀsw i l li n c r e a s e
the diagnosis of AMI by 20%–30%.
In our study, we identiﬁed 115 patients with an initial
negative, but subsequent positive, TnI out of population of
4510 ED patients undergoing serial cTnI testing. Within this
group,25patients(21.7%)presentedwith>8hofsymptoms.
At ﬁrst glance, this percentage seems to be unacceptably
high to exclude myocardial infarction on the basis of initial
troponin and symptom duration. However, one must take a
closer look at the details of these 25 patients (Table 4)p r i o r
to drawing any conclusions.
First, the new ECS-ACC recommended cutoﬀ for the
diagnosis of cardiac injury would have us use a much
lower value of troponin than the ROC cutoﬀ for AMI (i.e.,
0.06ng/mL instead of the current 0.6ng/mL). 18 of our 25
patients who presented to the ED >8 hours after symptom
onset had an initial TnI that was >0.06ng/mL. In other
words, those 18 patients had biochemical evidence of cardiac
injury at the time of arrival, requiring at least one additional
TnI level to further deﬁne their disease process. Many of
thesepatientshad nonischemicetiologiesresponsible forTnI
elevation (Table 5)[ 15].
Of the remaining 7 patients with no biochemical evi-
dence of cardiac injury on the initial troponin, two had a
ﬁnal primary diagnosis of ACS. The ﬁrst was a 75-year-old
woman with a history of diabetes, hypertension, and prior
MI, who presented with a week of worsening chest pain,
much worse “for one day” who presented with 10/10 pain.
Herdurationofsymptomswasrecordedas24hours,because
no more speciﬁc mention of an onset was made. The other
patient with an ultimate primary diagnosis of ACS was an
82-year-old female with a history of hypertension and heart
failure who presented with 3 days of worsening shortness of
breath. She had an LBBB on her initial ECG and an elevated
initial myoglobin value.Both ofthese patients were high-risk
patients who presented in extremis—neither of which would
have been “occult” NSTEMIs missed by the new guidelines.
It should be further noted that of these 7 patients, 5 of them
were >60 years old with at least one other cardiac risk factor
and the other 2 had recently used cocaine—risk factors or
practices that would havedeclared them as high-risk patients
who would typically be either admitted or at least subjected
to serial serum cardiac testing to exclude AMI.
5.Limitations
This study has several potential limitations that are typical
of a retrospective study design. Although the study pop-
ulation itself was identiﬁed using a laboratory database,
the remainder of the information was obtained from a
medical record review. Two authors did the entirety of
the data abstraction, which could call in to question both
the quality and the reliability of the data. In addition, the
abstractors were not blinded to the objective of the study
during the data abstraction. We feel that although this is a
potential source of signiﬁcant bias, we took steps to limit
this. For example, we queried our troponin database using a
broad deﬁnition of “initially negative, subsequentlypositive”
troponin. By using the 0.6ng/mL cutoﬀ for normal rather
than 0.06ng/mL, we were certain to catch all possible cases
that could have been missed with a single troponin. In
addition, when determining the duration of symptoms, we
required a speciﬁc mention to be made of a time of onset,
or else we accepted the much longer time that is implicated
by statements such as “one day”, even if it was clear that the
patienthadcontinuingorprogressivelyworseningsymptoms
upon arrival to the ED. This maximizes the number of
possible patients with >8 hours of symptoms upon arrival,
so that we would not miss any potential cases.
Another potential limitation to this study is the fact that
187 patients had a ﬁrst positive troponin upon arrival. Given
the possibility that these patients may have been seen in the
7 days prior and discharged home after a single troponin, we
queried our ED tracking system and found that 18 of these
patients had been seen in the week prior. Two of these 18
patients had been discharged home after a single negative
troponin.
6.Conclusions
T h eu s eo fan e g a t i v ei n i t i a lT n It o g e t h e rw i t has y m p t o m
onset of ≥8 hours prior to serum marker testing deﬁnes a
population at very low risk for a near-term diagnosis of ACS.ISRN Cardiology 7
Although we believe that our data considered in conjunction
with all of the prior studies addressing this topic suggest, it
is safe to exclude MI on the basis of symptom duration and
initial TnI, and further research is needed to better deﬁne
the population to which this strategy can be applied. The
next step will be a prospective observational study assessing
the ability of the combination of duration of symptoms,
single TnI with the new lower cutoﬀ, and ECG to exclude
the diagnosis of acute myocardial infarction. Patients will be
subclassiﬁed using the new grading system for myocardial
infarction whenever possible [16].
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